Acute Disease, Brain Ischemia, Cerebrovascular Accident
Conditions
Keywords
Acute ischemic stroke, abciximab, ReoPro, drug safety, drug efficacy, intracranial hemorrhage, stroke
Brief summary
The purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.
Detailed description
Abciximab is a drug that prevents platelets from sticking together and forming a clot. There are limited studies using abciximab in the treatment of strokes. This phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study is designed to assess the effectiveness and safety of abciximab for treatment of acute ischemic stroke, in helping dissolve clots in brain arteries so that blood and oxygen can flow better and there may be less brain damage. Safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. Patients will receive either Abciximab: 0.25 mg/kg bolus (to a maximum of 30 mg) followed by a 0.125 µg/kg/min infusion (to a maximum of 10 µg/min) for 12 hours or a bolus of placebo followed by infusion for 12 hours
Interventions
DRUGAbciximab
Sponsors
Eli Lilly and Company
Centocor, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosis of acute ischemic stroke with onset within 5 hours and 30 minutes before randomization and planned treatment initiation within 6 hours of onset * After 600 patients are enrolled in previous criteria, the new criteria for enrollment will be, patients with diagnosis of acute ischemic stroke with onset within 4 hours and 30 minutes before randomization and planned treatment initiation within 5 hours of onset
Exclusion criteria
* Patients who had participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial * Patients with symptoms suggestive of subarachnoid hemorrhage * Female patients known to be pregnant, lactating, or having a positive or indeterminate pregnancy test * Patients with neurological deficit that has led to stupor or coma * Patients with minor stroke
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of modified Rankin Scale responders at 3 months in the primary population. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with neurological recovery and all-cause mortality at 3 months in the primary population. Fatal intracranial-, nonfatal symptomatic parenchymal-, or other symptomatic intracranial hemorrhages though discharge at day 5 & 3 months | — |
Outcome results
None listed